<DOC>
	<DOCNO>NCT00563524</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability multiple dose ILV-094 administered subject psoriasis</brief_summary>
	<brief_title>Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Men Women nonchildbearing potential 18 year old . Physician Area Severity Index ( PASI ) great 11 . Physician Global Assessment ( PGA ) great 3 . Use investigational small molecule drug within 30 day first dose test article administration , use investigational biologic agent within 5 half life study day 1 , 90 day investigational biologics may long clinical duration effect . Live vaccine within 3 month test article administration study . Use biologic therapy within approximately 5 halflives test article administration . Approximate halflives biologic therapy approve psoriasis follow : Enbrel , 5 day ; Humira , 14 day ; Remicade , 9 day ; Amevive , 12 day ; Raptiva , 6 day . It recommend Amevive discontinue least 90 day long clinical duration action . Psoralen plus ultraviolet A radiation ( PUVA ) therapy within 4 week study day 1 . Ultraviolet B ( UVB ) therapy within 2 week study day 1 . Receipt systemic psoriasis therapy ( eg , oral retinoids , methotrexate , hydroxyurea , cyclosporine , azathioprine ) systemic corticosteroid within 4 week study day 1 . Topical steroid , topical vitamin A D analog preparation , anthralin within 2 week study day 1 . ( Exception : topical therapy , include steroid higher mild strength [ class 6 7 topical corticosteroid ] , permit scalp , axilla , face , groin , dose medication must keep stable throughout trial . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>